Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07333508

Fospropofol Disodium ED95 for Elderly Spinal Anesthesia Sedation

This study aims to determine the 95% effective dose (ED95) of fospropofol disodium, a new sedative drug, for adjuvant sedation during spinal anesthesia in elderly patients (aged 65 years and older) undergoing lower extremity surgery (e.g., hip/knee replacement, lower limb fracture fixation).

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Lower Extremity Surgery

Age range

65 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430030, China

About this study

Fospropofol disodium, the only water-soluble propofol prodrug marketed in China, features mild effects on respiratory and circulatory systems, low injection pain, no lipid metabolism-related adverse reactions, and suitable duration of action-making it a promising sedative for elderly patients. However, clinical data on its use in adjuvant sedation during spinal anesthesia are lacking, with no reports on its effective dose in this specific scenario. This prospective sequential trial aims to determine the 95% effective dose (ED95) of fospropofol disodium for sedation induction and maintenance in elderly patients (≥65 years) undergoing lower extremity surgery with spinal anesthesia, providing evidence-based guidance for safe and rational clinical use.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥65 years, no gender restriction
  • Scheduled for elective lower extremity surgery with spinal anesthesia
  • ASA physical status classification Ⅰ-Ⅲ
  • BMI 18.5-28.0
  • Written informed consent obtained from patients or their guardians

Exclusion criteria

  • Age <65 years；
  • Non-lower extremity surgery or conversion to general anesthesia；
  • ASA physical status classification Ⅳ or above；
  • BMI <18.5 or >28.0；
  • History of drug abuse or alcohol dependence；
  • Preoperative use of sedative or analgesic drugs；
  • Refusal to participate or inability to sign informed consent；
  • Severe arrhythmia or myocardial infarction within 3 months；
  • Severe liver or kidney dysfunction；
  • Severe respiratory diseases；
  • Coagulopathy；
  • Uncorrected severe electrolyte disturbance；
  • History of mental illness or cognitive impairment.

Treatment and study plan

fospropofol disodium

Drug

The initial induction dose is 6.0mg/kg, with a dose gradient of 0.5mg/kg (range: 4.0-8.0mg/kg). Sedation success is defined as a Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score ≤3 within 3 minutes after drug administration. Dose adjustment follows the k=3 sequential design: ① 3 consecutive successes → next patient receives a 0.5mg/kg lower dose; ② 1 failure → next patient receives a 0.5mg/kg higher dose; ③ 2 consecutive failures → skip the next gradient.

Immediately after successful induction (MOAA/S ≤3 within 3 minutes), continuous infusion of fospropofol disodium for sedation maintenance will be initiated. The initial maintenance rate is 6.0mg/kg/h, with a gradient of 0.5mg/kg/h (range: 3.0-7.5mg/kg/h). Maintenance success is defined as MOAA/S score ≤3 in ≥4 of 6 assessments (once every 10 minutes). Dose adjustment follows the k=3 sequential design: ① 3 consecutive successes → next patient receives a 0.5mg/kg/h lower rate; ② 1 failure → next patient receives a 0.

Primary outcomes

  1. 95% Effective Dose (ED95) of Fospropofol Disodium for Sedation in Elderly Patients Undergoing Lower Extremity Surgery with Spinal Anesthesia

    Time frame: ① Induction ED95: Assessed at 3 minutes after completion of the fospropofol disodium induction bolus; ② Maintenance ED95: Assessed throughout the intraoperative maintenance phase (6 evaluations, 10 minutes apart).

    The primary outcome is the 95% effective dose (ED95) of fospropofol disodium for adjuvant sedation during spinal anesthesia in elderly patients (≥65 years), including two key components: ① Induction ED95: The intravenous bolus dose at which 95% of patients achieve a Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score ≤3 within 3 minutes of administration (dose range: 4.0-8.0mg/kg, gradient: 0.5mg/kg); ② Maintenance ED95: The continuous intravenous infusion rate at which 95% of patients maintain an MOAA/S score ≤3 in ≥4 out of 6 intraoperative assessments (performed every 10 minutes) after successful induction (rate range: 3.0-7.5mg/kg/h, gradient: 0.5mg/kg/h). Both ED95 values (and their 95% confidence intervals [CI]) will be calculated using Probit regression analysis, with sedation success (effective=1, ineffective=0) as the dependent variable and dose/rate as the independent variable.

Secondary outcomes

  1. Induction Onset Time of Fospropofol Disodium

    Time frame: From the start of fospropofol disodium bolus injection to the first achievement of MOAA/S score ≤3, assessed up to 5 minutes.

    The time from the start of fospropofol disodium bolus injection (sedation induction phase) to the first achievement of a Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score ≤3.

  2. Recovery Time After Sedation Maintenance Discontinuation

    Time frame: From the moment of maintenance infusion cessation (start of surgical skin closure) to the time when MOAA/S score returns to 5, assessed up to 30 minutes.

    The time from the cessation of fospropofol disodium continuous infusion (start of surgical skin closure) to the recovery of MOAA/S score to 5 (full alertness, rapid response to name called in normal tone).

  3. Incidence of Respiratory Depression

    Time frame: Throughout the sedation period (from induction drug injection to maintenance infusion cessation) and within 10 minutes postoperatively.

    The proportion of patients with respiratory depression, defined as either respiratory rate <8 breaths per minute (bpm) or oxygen saturation (SpO₂) <90% (sustained for ≥10 seconds) during the entire sedation period (induction + maintenance).

  4. Intraoperative Changes in Mean Arterial Pressure (MAP)

    Time frame: Baseline (pre-sedation), 1/3/5 min post-induction, and every 10 minutes during maintenance.

    Change in mean arterial pressure (MAP) relative to baseline value (recorded after lumbar anesthesia stabilization pre-sedation). Key observation points include: 1 minute, 3 minutes, 5 minutes post-induction; and at each MOAA/S assessment time point during maintenance (every 10 minutes). The maximum decrease/increase percentage of MAP from baseline is calculated (e.g., maximum MAP decrease = [(baseline MAP - intraoperative minimum MAP)/baseline MAP] × 100%).

  5. Intraoperative Changes in Heart Rate (HR)

    Time frame: Baseline (pre-sedation), 1/3/5 min post-induction, and every 10 minutes during maintenance.

    Change in heart rate (HR) relative to baseline value (recorded after lumbar anesthesia stabilization pre-sedation). Key observation points include: 1 minute, 3 minutes, 5 minutes post-induction; and at each MOAA/S assessment time point during maintenance (every 10 minutes). The maximum decrease/increase percentage of HR from baseline is calculated (e.g., maximum HR decrease = [(baseline HR - intraoperative minimum HR)/baseline HR] × 100%).

  6. Incidence of Postoperative Adverse Reactions

    Time frame: Within 24 hours postoperatively (assessed during ward rounds or follow-up).

    The proportion of patients experiencing adverse reactions within 24 hours postoperatively, including:

    Cardiovascular reactions: Hypertension (SBP >160 mmHg or increase of ≥30% from baseline), tachycardia (HR >100 bpm); Gastrointestinal reactions: Nausea, vomiting; Neurological/psychological reactions: Postoperative agitation (restlessness, inability to cooperate with nursing care), dizziness; Others: Injection site pain, pruritus, paresthesia (recorded if persistent for ≥24 hours postoperatively).

Study contacts

Contact information is provided by the study sponsor or research team.

Xi-Jian Ke, Dr.

CONTACT

[email protected]

+86-027-83665431

Ya-Qun Zhou, Dr.

CONTACT

[email protected]

+86-027-83663171

Sponsors and collaborators

Lead sponsor

Ya-Qun Zhou

Other

Registry information

Official study title

95% Effective Dose (ED95) of Fospropofol Disodium for Adjunctive Sedation During Spinal Anesthesia in Elderly Patients Undergoing Lower Extremity Surgery

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
Jan 12, 2026
Registry last updated
Jan 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.